Abstract
Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.
Original language | English (US) |
---|---|
Article number | e28927 |
Journal | OncoImmunology |
Volume | 3 |
Issue number | 5 |
DOIs | |
State | Published - 2014 |
Keywords
- Glioblastoma
- Immunosuppression
- Immunotherapy
- Metabolism
- Tryptophan
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology